| Non-Small Cell Lung Carcinoma
Krazati vs Tafinlar + Mekinist
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Krazati vs Tafinlar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTafinlar has a higher rate of injection site reactions vs Krazati based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tafinlar but not Krazati, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Krazati
Tafinlar
At A Glance
Oral
Twice daily
KRAS G12C inhibitor
Oral
Twice daily
BRAF kinase inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Colorectal Neoplasms
- melanoma
- Non-Small Cell Lung Carcinoma
- Anaplastic thyroid carcinoma
- Low grade glioma
- Solid Neoplasm
Dosing
Non-Small Cell Lung Carcinoma 600 mg orally twice daily as a single agent until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
Colorectal Neoplasms 600 mg orally twice daily in combination with cetuximab until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
Melanoma 150 mg orally twice daily as single agent or in combination with trametinib 2 mg once daily, oral route.
Non-Small Cell Lung Carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Anaplastic thyroid carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Low grade glioma Weight-based dosing in pediatric patients (20-150 mg twice daily) in combination with trametinib, oral route.
Solid Neoplasm 150 mg orally twice daily in combination with trametinib 2 mg once daily in adults; weight-based dosing in pediatric patients >= 1 year, oral route.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, decreased appetite
Serious pneumonia, dyspnea, renal impairment, sepsis, respiratory failure, pleural effusion, anemia, cardiac failure
Most common (>= 20%) Pyrexia, rash, hyperkeratosis, headache, arthralgia, papilloma, alopecia, palmar-plantar erythrodysesthesia syndrome, chills, cough, nausea, vomiting, diarrhea, fatigue, dry skin, myalgia, constipation, decreased appetite, edema, hemorrhage, dyspnea, musculoskeletal pain, abdominal pain, epistaxis, dermatitis acneiform
Serious New primary malignancies (cutaneous and non-cutaneous RAS mutation-positive), hemorrhage, cardiomyopathy, uveitis, serious febrile reactions, serious skin toxicities including SCAR, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency, hemophagocytic lymphohistiocytosis
Pharmacology
Adagrasib is an irreversible KRAS G12C inhibitor that covalently binds to the mutant cysteine residue, locking KRAS G12C in its inactive GDP-bound state and preventing downstream signaling without affecting wild-type KRAS.
Dabrafenib is a BRAF kinase inhibitor that targets mutated BRAF V600E, V600K, and V600D enzymes, inhibiting cell growth in BRAF V600 mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Krazati
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Tafinlar
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Krazati
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Tafinlar
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Krazati
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tafinlar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Krazati.
No savings programs available for Tafinlar.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KrazatiView full Krazati profile
TafinlarView full Tafinlar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.